# Progressive Dysregulation of Endocannabinoid System in ADPKD > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-therapeutic-target-adpkd/ > **Published:** 2026-03-16T12:51:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:52-04:00 > **Clinical Summary:** Research identifies the endocannabinoid system therapeutic target potential in autosomal dominant polycystic kidney disease (ADPKD) progression and treatment. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologySafety Why This Matters This research identifies the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) as a potential therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), suggesting that cannabinoid-based interventions could slow disease progression by modulating renal inflammation and metabolic dysfunction. Clinicians managing ADPKD patients currently lack disease-modifying options beyond blood pressure control and tolvaptan, so evidence of CB1R dysregulation opens a new avenue for [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) that could improve patient outcomes. Understanding this mechanism also helps contextualize why some patients report symptom improvement with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and informs future [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to establish safe, effective cannabinoid dosing for kidney disease. Clinical Summary This preclinical research demonstrates that the endocannabinoid system, particularly CB1 receptor signaling, becomes progressively dysregulated in autosomal dominant polycystic kidney disease (ADPKD) and may contribute to the disease’s characteristic renal inflammation and metabolic dysfunction. The study suggests that CB1R dysfunction parallels ADPKD progression and could be a therapeutic target to slow kidney deterioration through modulation of inflammatory pathways. These findings provide mechanistic rationale for investigating cannabinoid-based therapies in ADPKD, a progressive genetic disorder with limited treatment options and high morbidity. While translating these preclinical observations into clinical trials will require substantial additional research, clinicians managing ADPKD patients should be aware that cannabinoid therapeutics may eventually offer a disease-modifying approach beyond current symptom management. Patients with ADPKD should be counseled that while cannabis or cannabinoid products are not yet evidence-based treatments, ongoing research into endocannabinoid system dysfunction may identify future therapeutic opportunities. Dr. Caplan’s Take “What this research tells us is that cannabinoid dysregulation isn’t incidental to polycystic kidney disease but central to its pathophysiology, which means we should be studying CB1-targeted interventions not as fringe therapy but as legitimate disease-modifying candidates for patients who currently have very limited options.” Clinical Perspective While preclinical evidence suggests the endocannabinoid system may contribute to kidney disease progression in autosomal dominant polycystic kidney disease (ADPKD), translation to clinical practice remains uncertain and premature. The study’s mechanistic findings in animal models provide biological plausibility for CB1R-targeted interventions, but human ADPKD involves multiple genetic and environmental factors that may not be fully captured in experimental systems, and the long-term safety and efficacy of cannabinoid-based therapies in progressive renal disease have not been established. Current standard-of-care management focuses on tolvaptan and lifestyle modifications with established clinical benefit, whereas cannabinoid therapies for ADPKD remain investigational. Clinicians should be cautious about patient inquiries regarding cannabis or cannabinoid products for kidney disease, as off-label use could delay proven treatments and introduce additional variables that complicate 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Progressive+endocannabinoid+system+dysregulation+in+autosomal+dominant+polycystic+...+%40drcaplan&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs10020-026-01457-w)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs10020-026-01457-w)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Progressive+endocannabinoid+system+dysregulation+in+autosomal+dominant+polycystic+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs10020-026-01457-w)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - New study uncovers worrying way excessive drinking for 35 years impacts your brain 📰 Source: [https://link.springer.com/article/10.1186/s10020-026-01457-w](https://link.springer.com/article/10.1186/s10020-026-01457-w) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Identified as Therapeutic Target for Pancreatitis](https://cedclinic.com/endocannabinoid-system-identified-as-therapeutic-target-for-pancreatitis/) Explore how the endocannabinoid system serves as a therapeutic target in pancreatitis, highlighting parallels in inflammatory disease mechanisms. [Learn More](https://cedclinic.com/endocannabinoid-system-identified-as-therapeutic-target-for-pancreatitis/) [Some Cannabinoids May Ease Common Chronic Pain Conditions, Study Finds](https://cedclinic.com/some-cannabinoids-may-ease-common-chronic-pain-conditions-study-finds/) Discover research on cannabinoids' potential to modulate inflammation and pain, relevant to kidney disease symptom management. [Read Study](https://cedclinic.com/some-cannabinoids-may-ease-common-chronic-pain-conditions-study-finds/) [FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Treatment](https://cedclinic.com/fda-grants-breakthrough-therapy-designation-to-investigational-cannabis-derived/) Learn about FDA breakthrough therapy designation for cannabis-derived treatments, underscoring the clinical potential of [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). [Explore Details](https://cedclinic.com/fda-grants-breakthrough-therapy-designation-to-investigational-cannabis-derived/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).